Clearside Biomedical Return on Equity

Clearside Biomedical (CLSD) currently reports a ROE of 48.19%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Clearside Biomedical's ROE history and peer comparisons.

Clearside Biomedical's ROE of 48.19% is higher than the Healthcare sector average of 21.67%. That is roughly 122.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Clearside Biomedical's current 48.19% should be judged against Healthcare norms (sector average: 21.67%) and against CLSD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 48.19%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Clearside Biomedical, and consider following CLSD for alerts when major investors trade the stock.

Clearside Biomedical is classified in the Healthcare sector. On ROE, it currently shows 48.19% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLSD with unrelated industries.